SEC Filings

SEC Filings

Other Filings
Filing Description Filing Type Filing Date Event Date  
10-K 10-K/A 4/28/2017 12/31/2016
8-K 8-K 4/11/2017 4/11/2017
Abstract: 8-K filed by Diffusion Pharmaceuticals Inc. (DFFN) covering .
13-D SC 13G/A 4/6/2017
8-K 8-K 4/3/2017 3/31/2017
Abstract: 8-K filed by Diffusion Pharmaceuticals Inc. (DFFN) covering Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Disclosure; and Financial Statements and Exhibits.
8-K 8-K 3/31/2017 3/31/2017
Abstract: 8-K filed by Diffusion Pharmaceuticals Inc. (DFFN) covering Results of Operations and Financial Condition and Financial Statements and Exhibits.
10-K 10-K 3/31/2017 12/31/2016
Registration Statement D 3/16/2017
8-K 8-K 3/15/2017 3/13/2017
Abstract: 8-K filed by Diffusion Pharmaceuticals Inc. (DFFN) covering Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities; Material Modification to Rights of Security Holders; Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; and Financial Statements and Exhibits.
13-D SC 13G/A 2/2/2017
8-K 8-K/A 1/27/2017 1/23/2017
Abstract: 8-K filed by Diffusion Pharmaceuticals Inc. (DFFN) covering Regulation FD Disclosure and Financial Statements and Exhibits.
8-K 8-K 1/26/2017 1/23/2017
Abstract: 8-K filed by Diffusion Pharmaceuticals Inc. (DFFN) covering Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Regulation FD Disclosure; and Financial Statements and Exhibits.
8-K 8-K 1/9/2017 1/6/2017
Abstract: Registrant announced the results of special meeting of stockholders held Jan. 6.
Proxy DEF 14A 12/8/2016 1/6/2017
Proxy PRE 14A 11/28/2016 1/6/2017
8-K 8-K 11/14/2016 11/14/2016
Abstract: On Nov. 14, registrant reported its financial results for the quarter ended Sept. 30.
10-Q 10-Q 11/14/2016 9/30/2016
8-K 8-K 11/8/2016 11/8/2016
Abstract: On Nov. 8, registrant announced that its shares of common stock were approved for listing on the Nasdaq capital market.
Registration Statement 8-A12B 11/8/2016
Abstract: Registrant filed a description of its common stock, incorporated by reference into its registration statement on Form 10-K, in order to register it under the Securities Exchange Act of 1934.
8-K 8-K 10/13/2016 10/12/2016
Abstract: 8-K filed by Diffusion Pharmaceuticals, Inc. (DFFN) covering Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers and Financial Statements and Exhibits.
8-K 8-K 10/3/2016 9/27/2016
Abstract: 8-K filed by Diffusion Pharmaceuticals, Inc. (DFFN) covering Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Unregistered Sales of Equity Securities; and Financial Statements and Exhibits.

Displaying 1 to 20 (of 140 filings)